Inhaled Ventavis® (iloprost) Inhalation Solution Privacy Policy  |  Terms & Conditions  |  Contact Us  |  Site Map  |  Important Safety Information   

*Indication

Ventavis is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve a composite endpoint consisting of exercise tolerance, symptoms (NYHA Class), and lack of deterioration. Studies establishing effectiveness included predominately patients with NYHA Functional Class III-IV symptoms and etiologies of idiopathic or heritable PAH (65%) or PAH associated with connective tissue disease (23%).
Inhaled Ventavis® (iloprost) Inhalation Solution
PAH Pathways - Actelion Services & Support
Download 20 mcg/mL Medication Order Form
Download the
Ventavis Patient
Enrollment Forms

Contact Us

Actelion Pharmaceuticals US, Inc.
5000 Shoreline Court, Suite 200
South San Francisco, CA 94080
Phone 1-866-ACTELION (1-866-228-3546)
Fax 1-415-268-9515
Monday through Friday,
9 AM to 8 PM (ET)
6 AM to 5 PM (PT)

Medical Information

Patients should always talk with their healthcare team first if there are any questions about their individual treatment.

For further medical information on Actelion treatments or pulmonary arterial hypertension (PAH), please contact our Medical Information Department by calling 1-866-ACTELION (1-866-228-3546), sending a fax to 1-415-268-9515.

The hours of operation for the Medical Information Department are 6:00 a.m. to 4:00 p.m. PST, Monday through Friday, excluding holidays.

Automatic Request Form

Required Fields are in red.

First Name:
Last Name:
I am a:
Institution:
Address 1:
Address 2:
City:
State: Zip:
Email:
Confirm Email:
Phone Number:
Information Request
(250 Character Limit)

This form is not for reporting information about any medication side effects. To report suspected adverse reactions, contact Actelion at 1-866-ACTELION (1-866-228-3546), or the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch
Verification:
 

IMPORTANT SAFETY INFORMATION

Hypotension leading to syncope has been observed; Ventavis should therefore not be initiated in patients with systolic blood pressure less than 85 mmHG. Stop Ventavis immediately if signs of pulmonary edema occur; this may be a sign of pulmonary venous hypertension. Ventavis inhalation may cause brochospasm and patients with a history of hyperreactive airway disease may be more sensitive. Serious adverse events reported at a rate of less than 3% included congestive heart failure, chest pain, supraventricular tachycardia, dyspnea, peripheral edema, and kidney failure. Vital signs should be monitored while initiating Ventavis. In clinical studies, common adverse reactions due to Ventavis included vasodilation (flushing), cough, headache, trismus, and insomnia. Ventavis has the potential to increase risk of bleeding, particularly in patients maintained on anticoagulants.

Please see full Prescribing Information

† In the AIR pivotal trial, Ventavis delivered significant patient improvement in a combined endpoint consisting of ≥10% increase in 6MWD, improvement in NYHA functional class, and lack of deterioration or death (p=0.0033).

I-neb AAD System User Guide
Respironics and I-neb are trademarks of or belonging to Koninklijke Philips Electronics N.V.

 

For more information about Ventavis, please call
1-866-ACTELION
(1-866-228-3546).

Privacy Policy  |  Terms & Conditions  |  Contact Us  |  Site Map  |  Important Safety Information

THIS SITE IS INTENDED FOR U.S. AUDIENCES ONLY.
SECOND WIND is a licensed trademark of Pulmonary Rehabilitation Associates.
©2012 Actelion Pharmaceuticals US, Inc. All rights reserved.

07 141 01 11 0411

ACTELION